ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 461
    Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry
  • Abstract Number: 2850
    Etanercept Treatment in Psoriatic Arthritis:  Need for Co-Medication?
  • Abstract Number: 643
    Ethnicity of Sjögren’s Syndrome
  • Abstract Number: 1506
    EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
  • Abstract Number: 485
    Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
  • Abstract Number: 1296
    Evaluating Inter-Rater Reliability in Joint Count to Promote Quality and Trust in a Clinical Arthritis Care Team
  • Abstract Number: 2755
    Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis
  • Abstract Number: 76
    Evaluating Weather’s Effect on Fibromyalgia Patients Using the Revised Fibromyalgia Impact Questionnaire and the Brief Pain Inventory
  • Abstract Number: 853
    Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases
  • Abstract Number: 3065
    Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Takayasu’s Arteritis in Large Healthcare Administrative Databases
  • Abstract Number: 3244
    Evaluation of a Self-Directed Walking Program in Hispanics with Arthritis
  • Abstract Number: 2663
    Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity
  • Abstract Number: 1657
    Evaluation of Bone and Joint Proteins for Prognostic Association with Radiographic Progression and Disease Activity in Methotrexate Inadequate Responder Rheumatoid Arthritis Patients in a Sarilumab Phase 3 Study
  • Abstract Number: 1524
    Evaluation of Changes in Cardiovascular Risk Factors Among Patients with RA Prescribed Biologic Dmards
  • Abstract Number: 2310
    Evaluation of Fibromyalgia Syndrome in Patients Undergoing Peritoneal Dialysis
  • « Previous Page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • …
  • 218
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology